Walker, Ulrich A.
Jaeger, Veronika K.
Bruppacher, Katharina M.
Dobrota, Rucsandra
Arlettaz, Lionel
Banyai, Martin
Beron, Jörg
Chizzolini, Carlo
Groechenig, Ernst
Mueller, Rüdiger B.
Spertini, François
Villiger, Peter M.
Distler, Oliver
Funding for this research was provided by:
Actelion Pharma Schweiz AG
Article History
Received: 23 July 2018
Accepted: 25 September 2018
First Online: 25 October 2018
Ethics approval and consent to participate
: Ethics approval was obtained from the following ethics committees: Ethikkommission Nordwest- und Zentralschweiz, Kantonale Ethikkommission Kanton Aargau, Commission Cantonale d’Éthique de la Recherche Genève, Commission cantonal (VD) d’éthique de la recherché sur l’être humain, Kantonale Ethikkommission Bern, Ethikkommission Ostschweiz and Kantonale Ethikkommission Zürich.
: Not applicable.
: VKJ received travel grant and travel support from Actelion Pharma Schweiz AG. KMB was a former full-time employee of Actelion Pharma Schweiz AG. RD received research funding through an Articulum Fellowship sponsored by Pfizer (2013–2014), a EULAR training bursary and from the FP-7-DeSScipher project, and speaker fees from Actelion. JB is a full-time employee of Actelion Pharma Schweiz AG. CC received travel support and speaker fees from Actelion and Boehringer Ingelheim. OD has a consultancy relationship and/or research funding from AnaMar, Bayer, Boehringer Ingelheim, Catenion, CSL Behring, ChemomAb, Roche, GSK, Inventiva, Italfarmaco, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Sanofi and UCB in the area of potential treatments of scleroderma and its complications; in addition, OD has licensed patent mir-29 for the treatment of systemic sclerosis. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.